Projekt

A multicenter, open-label, randomized, phase 2 study of venetoclax and azacitidine plus cusatuzumab versus venetoclax and azacitidine alone in newly diagnosed AML patients who are not candidates for intensive therapy

Laufend - Rekrutierung – laufend · 2024 bis 2028

Schittenhelm Marcus, Dei Cas Alissa